Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
$0.17
$0.19
$0.16
$1.09
$5.00M0.191.92 million shs109,544 shs
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
$6.03
-3.7%
$5.94
$5.26
$11.38
$250.74M0.66577,230 shs379,009 shs
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
$5.59
$5.59
$3.11
$5.60
$955.06M1.153.29 million shs6 shs
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
$8.98
+5.0%
$15.25
$8.46
$21.70
$230.88M1.33212,445 shs201,977 shs
Surmodics, Inc. stock logo
SRDX
Surmodics
$26.92
+6.0%
$29.14
$16.79
$39.41
$383.34M1.0158,598 shs52,914 shs
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
+0.42%+1.63%-9.03%-24.19%-79.48%
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
-3.67%-7.37%+12.50%+0.50%-31.24%
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
0.00%0.00%0.00%0.00%0.00%
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
+5.03%-7.42%-42.77%-43.20%-37.11%
Surmodics, Inc. stock logo
SRDX
Surmodics
+6.03%+1.20%-2.68%-22.64%+13.87%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
N/AN/AN/AN/AN/AN/AN/AN/A
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
4.6433 of 5 stars
3.54.00.04.22.43.31.3
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
0.9498 of 5 stars
3.42.00.00.01.10.00.6
Surmodics, Inc. stock logo
SRDX
Surmodics
4.0447 of 5 stars
3.52.00.03.41.61.71.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
N/AN/AN/AN/A
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
3.00
Buy$14.25136.32% Upside
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
N/AN/AN/AN/A
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
2.80
Moderate Buy$27.80209.58% Upside
Surmodics, Inc. stock logo
SRDX
Surmodics
3.00
Buy$59.00119.17% Upside

Current Analyst Ratings

Latest ANGO, AFIB, ATRS, SRDX, and RCEL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/11/2024
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
4/10/2024
Surmodics, Inc. stock logo
SRDX
Surmodics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$47.00
4/5/2024
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$12.00
2/23/2024
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$19.00 ➝ $21.00
2/23/2024
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$22.00 ➝ $25.00
2/1/2024
Surmodics, Inc. stock logo
SRDX
Surmodics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$44.00 ➝ $47.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
$7.16M0.70N/AN/A($0.03) per share-5.61
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
$324.01M0.75$1.06 per share5.71$9.64 per share0.63
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
$183.98M5.19$0.13 per share43.89$1.03 per share5.43
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
$50.14M4.60N/AN/A$1.92 per share4.68
Surmodics, Inc. stock logo
SRDX
Surmodics
$132.58M2.89$0.80 per share33.78$8.48 per share3.17

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
-$81.66M-$1.24N/AN/A-166.79%-35.31%-13.43%5/9/2024 (Estimated)
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
-$52.44M-$4.84N/AN/AN/A-60.21%-3.48%-2.68%7/10/2024 (Estimated)
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
$46.29M$0.2423.2925.41N/A21.90%7.43%4.92%N/A
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
-$35.38M-$1.40N/AN/AN/A-70.56%-54.80%-38.08%5/13/2024 (Confirmed)
Surmodics, Inc. stock logo
SRDX
Surmodics
-$1.54M$0.3870.84N/AN/A3.99%8.06%5.11%5/1/2024 (Confirmed)

Latest ANGO, AFIB, ATRS, SRDX, and RCEL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2024N/A
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
-$0.26N/A+$0.26N/AN/AN/A  
5/1/2024N/A
Surmodics, Inc. stock logo
SRDX
Surmodics
-$0.36N/A+$0.36N/AN/AN/A  
2/22/2024Q4 2023
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
-$0.34-$0.28+$0.06-$0.28$14.10 million$14.20 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
N/AN/AN/AN/AN/A
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
N/AN/AN/AN/AN/A
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
N/AN/AN/AN/AN/A
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
N/AN/AN/AN/AN/A
Surmodics, Inc. stock logo
SRDX
Surmodics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
1.10
2.44
2.22
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
N/A
2.29
1.62
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
0.10
3.08
2.87
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
0.81
7.88
7.46
Surmodics, Inc. stock logo
SRDX
Surmodics
0.24
4.84
3.97

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
56.91%
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
89.43%
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
50.41%
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
27.66%
Surmodics, Inc. stock logo
SRDX
Surmodics
96.63%

Insider Ownership

CompanyInsider Ownership
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
3.50%
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
5.10%
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
5.90%
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
2.05%
Surmodics, Inc. stock logo
SRDX
Surmodics
8.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
23029.72 million28.68 millionOptionable
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
81540.06 million38.01 millionOptionable
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
201170.85 million160.77 millionOptionable
AVITA Medical, Inc. stock logo
RCEL
AVITA Medical
20725.71 million25.18 millionOptionable
Surmodics, Inc. stock logo
SRDX
Surmodics
37614.24 million12.97 millionOptionable

ANGO, AFIB, ATRS, SRDX, and RCEL Headlines

SourceHeadline
Surmodics (NASDAQ:SRDX) Downgraded by StockNews.com to BuySurmodics (NASDAQ:SRDX) Downgraded by StockNews.com to Buy
americanbankingnews.com - April 24 at 2:22 AM
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
businesswire.com - April 19 at 7:00 AM
Will SurModics (SRDX) Report Negative Q2 Earnings? What You Should KnowWill SurModics (SRDX) Report Negative Q2 Earnings? What You Should Know
finance.yahoo.com - April 17 at 2:18 PM
Will SurModics (SRDX) Report Negative Q2 Earnings? What You Should KnowWill SurModics (SRDX) Report Negative Q2 Earnings? What You Should Know
zacks.com - April 17 at 11:06 AM
Surmodics (NASDAQ:SRDX) Upgraded by StockNews.com to "Strong-Buy"Surmodics (NASDAQ:SRDX) Upgraded by StockNews.com to "Strong-Buy"
americanbankingnews.com - April 17 at 3:42 AM
Surmodics (NASDAQ:SRDX) Rating Increased to Strong-Buy at StockNews.comSurmodics (NASDAQ:SRDX) Rating Increased to Strong-Buy at StockNews.com
marketbeat.com - April 16 at 11:04 PM
Investors in Surmodics (NASDAQ:SRDX) have unfortunately lost 54% over the last three yearsInvestors in Surmodics (NASDAQ:SRDX) have unfortunately lost 54% over the last three years
finance.yahoo.com - April 13 at 8:40 AM
Q1 2025 Earnings Estimate for Surmodics, Inc. Issued By Zacks Research (NASDAQ:SRDX)Q1 2025 Earnings Estimate for Surmodics, Inc. Issued By Zacks Research (NASDAQ:SRDX)
marketbeat.com - April 11 at 7:42 AM
Analysts Offer Insights on Healthcare Companies: Genprex (GNPX) and SurModics (SRDX)Analysts Offer Insights on Healthcare Companies: Genprex (GNPX) and SurModics (SRDX)
markets.businessinsider.com - April 10 at 4:59 PM
Surmodics (SRDX) "Buy" Rating Reiterated at Needham & Company LLCSurmodics' (SRDX) "Buy" Rating Reiterated at Needham & Company LLC
marketbeat.com - April 10 at 11:26 AM
Q4 2025 EPS Estimates for Surmodics, Inc. Boosted by Zacks Research (NASDAQ:SRDX)Q4 2025 EPS Estimates for Surmodics, Inc. Boosted by Zacks Research (NASDAQ:SRDX)
marketbeat.com - April 10 at 8:44 AM
New Strong Buy Stocks for April 9thNew Strong Buy Stocks for April 9th
zacks.com - April 9 at 7:16 AM
Should You Think About Buying Surmodics, Inc. (NASDAQ:SRDX) Now?Should You Think About Buying Surmodics, Inc. (NASDAQ:SRDX) Now?
finance.yahoo.com - March 23 at 1:09 PM
Heres Why You Should Hold Surmodics (SRDX) Stock for NowHere's Why You Should Hold Surmodics (SRDX) Stock for Now
zacks.com - March 20 at 12:30 PM
Are Surmodics, Inc.s (NASDAQ:SRDX) Mixed Financials Driving The Negative Sentiment?Are Surmodics, Inc.'s (NASDAQ:SRDX) Mixed Financials Driving The Negative Sentiment?
finance.yahoo.com - March 2 at 1:31 PM
Surmodics to Participate in Upcoming Investor Conferences in March and AprilSurmodics to Participate in Upcoming Investor Conferences in March and April
businesswire.com - February 27 at 8:00 AM
SYK Jun 2024 290.000 putSYK Jun 2024 290.000 put
ca.finance.yahoo.com - February 6 at 1:03 PM
Heres What Analysts Are Forecasting For Surmodics, Inc. (NASDAQ:SRDX) After Its First-Quarter ResultsHere's What Analysts Are Forecasting For Surmodics, Inc. (NASDAQ:SRDX) After Its First-Quarter Results
finance.yahoo.com - February 4 at 9:23 AM
Heres Why Shareholders May Want To Be Cautious With Increasing Surmodics, Inc.s (NASDAQ:SRDX) CEO Pay PacketHere's Why Shareholders May Want To Be Cautious With Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Pay Packet
finance.yahoo.com - February 2 at 5:33 PM
Surmodics, Inc. (NASDAQ:SRDX) Q1 2024 Earnings Call TranscriptSurmodics, Inc. (NASDAQ:SRDX) Q1 2024 Earnings Call Transcript
finance.yahoo.com - February 2 at 12:26 PM
Surmodics (SRDX) Q1 Earnings Top Estimates, Revises FY24 ViewSurmodics (SRDX) Q1 Earnings Top Estimates, Revises FY24 View
finance.yahoo.com - February 2 at 12:26 PM
Surmodics Shares Decline 10% on Investors Lofty Expectations for SurVeilSurmodics Shares Decline 10% on Investors' Lofty Expectations for SurVeil
marketwatch.com - February 1 at 5:53 PM
Surmodics Inc (SRDX) Posts Revenue Growth and Narrows Net Loss in Q1 Fiscal 2024Surmodics Inc (SRDX) Posts Revenue Growth and Narrows Net Loss in Q1 Fiscal 2024
finance.yahoo.com - February 1 at 5:53 PM
Surmodics beats top-line and bottom-line estimates; updates FY24 outlookSurmodics beats top-line and bottom-line estimates; updates FY24 outlook
msn.com - February 1 at 12:52 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Acutus Medical logo

Acutus Medical

NASDAQ:AFIB
Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. The company was incorporated in 2011 and is headquartered in Carlsbad, California.
AngioDynamics logo

AngioDynamics

NASDAQ:ANGO
AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company's thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. In addition, it offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. The company also provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
Antares Pharma logo

Antares Pharma

NASDAQ:ATRS
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey.
AVITA Medical logo

AVITA Medical

NASDAQ:RCEL
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
Surmodics logo

Surmodics

NASDAQ:SRDX
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.